Setting the record straight on the Bayh-Dole Act and March-in

The National Institutes of Health (NIH) recently made the right decision to uphold the Bayh-Dole Act and not seize patent rights on an innovative medicine by exploiting part of the law known as the “march-in” provision. However, the issue of future patent right seizures remains a concern because the Biden Administration has left the door open to revising the longstanding Bayh-Dole framework. Erosion of Bayh-Dole would put the entire U.S. innovation ecosystem at risk. It’s important to un derstand the immense success of Bayh-Dole and the potential devastating impacts of rewriting the march-in provision to allow the government to seize patent rights solely on the basis of product pricing.What is Bayh-Dole? Congress passed the bipartisan Bayh-Dole Act in 1980 to spur innovation and create a framework in which research institutions receiving federal funds could patent their inventions and license them to private entities to benefit the public. 
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Intellectual Property Source Type: news